LIGAND PHARMA (LGDN.SG) (LGDN STU) stock market data APIs
€141.2824
1.14(0.8%)
as of September 18, 2025
Try our APIs with
free plan!
LIGAND PHARMA (LGDN.SG) Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for LGDN.SG.
Prev. Close
141.2824
Open
142.4216
High
142.4216
Low
141.2824
52 wk Range
85-144
Market Cap
2 130 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get LIGAND PHARMA (LGDN.SG) data using free add-ons & libraries
Get LIGAND PHARMA (LGDN.SG) Fundamental Data
LIGAND PHARMA (LGDN.SG) Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LIGAND PHARMA (LGDN.SG) News
New
LGND: Pelthos To Become Public Company
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) announced that it had identified a suitor to take its subsidiary Pelthos Therapeu...
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Ligand Pharmaceuticals Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™ ZELSUVMI is a...
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pel...
Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value
As the U.S. stock market faces a turbulent period with major indices like the Dow Jones and S&P 500 on track for their worst week in two years, concerns about tariffs and economic health continue to d...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
